Related Experiment Videos
Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest
1ABL Basic Research Program, NCI-FCRDC, Frederick, Maryland 21702, USA.
Abstract:
Suppression of tumor cell growth by p53 results from the activation of both apoptosis and cell cycle arrest, functions which have been shown to be separable activities of p53. We have characterized a series of p53 mutants with amino acid substitutions at residue 175 and show that these mutants fall into one of three classes: class I, which is essentially wild type for apoptotic and cell cycle arrest functions; class II, which retains cell cycle arrest activity but is impaired in the induction of apoptosis; and class III, which is defective in both activities. Several residue 175 mutants which retain cell cycle arrest function have been detected in cancers, and we show that these have lost apoptotic function. Furthermore, several class II mutants have been found to be temperature sensitive for apoptotic activity while showing constitutive cell cycle arrest function. Taken together, these mutants comprise an excellent system with which to investigate the biochemical nature of p53-mediated apoptosis, the function of principal importance in tumor suppression. All of the mutants that showed loss of apoptotic function also showed defects in the activation of promoters from the potential apoptotic targets Bax and the insulin-like growth factor-binding protein 3 gene (IGF-BP3), and a correlation between full apoptotic activity and activation of both of these promoters was also seen with the temperature-sensitive mutants. However, a role for additional apoptotic activities of p53 was suggested by the observation that some mutants retained significant apoptotic function despite being impaired in the activation of Bax- and IGF-BP3-derived promoters. In contrast to the case of transcriptional activation, a perfect correlation between transcriptional repression of the c-fos promoter and the ability to induce apoptosis was seen, although the observation that Bax expression induced a similar repression of transcription from this promoter suggests that this may be a consequence, rather than a cause, of apoptotic death.
Insights
p53 protein mutations can impair tumor suppression by separating cell cycle arrest from apoptosis. Some cancer-associated p53 mutants lose apoptosis function while retaining cell cycle arrest, impacting tumor growth control.
Area of Science:
- Molecular Biology
- Cancer Biology
- Genetics
Background:
- The tumor suppressor protein p53 regulates cell cycle arrest and apoptosis, crucial for preventing tumor cell growth.
- These two functions, apoptosis induction and cell cycle arrest, are separable activities of p53.
- Mutations in p53 are common in human cancers, often leading to loss of tumor suppressive functions.
Purpose of the Study:
- To characterize p53 mutants with substitutions at residue 175.
- To investigate the relationship between cell cycle arrest, apoptosis, and tumor suppression.
- To understand the biochemical basis of p53-mediated apoptosis.
Main Methods:
- Characterization of p53 mutants with amino acid substitutions at residue 175.
- Assaying apoptosis and cell cycle arrest activities of p53 mutants.
- Analyzing the activation of target gene promoters (Bax, IGF-BP3, c-fos) by p53 mutants.
Main Results:
- p53 mutants were classified into three groups based on apoptosis and cell cycle arrest functions.
- Class II mutants retained cell cycle arrest but lost apoptosis induction.
- Cancer-associated p53 mutants at residue 175 often lost apoptotic function but retained cell cycle arrest.
- Mutants with lost apoptotic function showed defects in activating Bax and IGF-BP3 promoters.
- A correlation was observed between apoptosis induction and repression of the c-fos promoter.
Conclusions:
- p53 mutants found in cancers can lose critical apoptotic functions while maintaining cell cycle arrest.
- These findings highlight the importance of p53-mediated apoptosis in tumor suppression.
- The characterized mutants provide a system to study the molecular mechanisms of p53-induced apoptosis.